Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

BENLYSTA Solution for injection (2019)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Benlysta 200 mg solution for injection in pre-filled pen. Benlysta 200 mg solution for injection in pre-filled syringe.

Qualitative and quantitative composition

<u>Pre-filled pen:</u> Each 1-ml pre-filled pen contains 200 mg of belimumab. <u>Pre-filled syringe:</u> Each 1-ml pre-filled syringe contains 200 mg of belimumab. Belimumab is a human, IgG1λ monoclonal ...

Pharmaceutical form

Solution for injection in pre-filled pen (injection). Solution for injection in pre-filled syringe (injection). A clear to opalescent, colourless to pale yellow solution, with a pH of 6.

Therapeutic indications

Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low ...

Posology and method of administration

Benlysta treatment should be initiated and supervised by a qualified physician experienced in the diagnosis and treatment of SLE. It is recommended that the first subcutaneous injection of Benlysta should ...

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Special warnings and precautions for use

Traceability In order to improve traceability of biological medicinal products, the tradename and the batch number of the administered product should be clearly recorded. Benlysta has not been studied ...

Interaction with other medicinal products and other forms of interaction

No in vivo interaction studies have been performed. The formation of some CYP450 enzymes is suppressed by increased levels of certain cytokines during chronic inflammation. It is not known if belimumab ...

Fertility, pregnancy and lactation

Women of childbearing potential/Contraception in males and females Women of childbearing potential must use effective contraception during Benlysta treatment and for at least 4 months after the last treatment. ...

Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. No detrimental effects on such activities are predicted from the pharmacology of belimumab. The clinical status of ...

Undesirable effects

Summary of the safety profile The safety of belimumab in patients with SLE has been evaluated in 3 pre-registration, placebo-controlled intravenous studies, 1 placebo-controlled subcutaneous study, and ...

Overdose

There is limited clinical experience with overdose of Benlysta. Adverse reactions reported in association with cases of overdose have been consistent with those expected for belimumab. Two doses up to ...

Pharmacodynamic properties

Pharmacotherapeutic group: Selective immunosuppressants ATC code: L04AA26 Mechanism of action Belimumab is a human IgG1λ monoclonal antibody specific for soluble human B Lymphocyte Stimulator protein (BLyS, ...

Pharmacokinetic properties

The subcutaneous pharmacokinetic parameters below are based on population parameter estimates from 661 subjects, comprised of 554 SLE patients and 107 healthy subjects, who received Benlysta subcutaneously. ...

Preclinical safety data

Non-clinical data reveal no special hazard for humans based on studies of repeated dose toxicity and toxicity to reproduction. Intravenous and subcutaneous administration to monkeys resulted in the expected ...

List of excipients

Arginine hydrochloride Histidine Histidine monohydrochloride Polysorbate 80 Sodium chloride Water for injections

Incompatibilities

None known.

Shelf life

3 years.

Special precautions for storage

Store in a refrigerator (2°C to 8°C). Do not freeze. Store in the original carton in order to protect from light. A single Benlysta pre-filled syringe or pre-filled pen can be stored at temperatures up ...

Nature and contents of container

Pre-filled pen: 1 ml solution in a type 1 glass syringe with a fixed needle (stainless steel) in a pre-filled pen. Available in packs of 1 or 4 pre-filled pens and multipack containing 12 single-dose pre-filled ...

Special precautions for disposal and other handling

Comprehensive instructions for subcutaneous administration of Benlysta in a pre-filled pen or pre-filled syringe are provided at the end of the package leaflet (see Step-by-step instructions). Any unused ...

Marketing authorization holder

GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland

Marketing authorization number(s)

EU/1/11/700/003 1 pre-filled pen EU/1/11/700/004 4 pre-filled pens EU/1/11/700/005 12 (3x4) pre-filled pens (multipack) EU/1/11/700/006 1 pre-filled syringe EU/1/11/700/007 4 pre-filled syringes

Date of first authorization / renewal of the authorization

Date of first authorisation: 13 July 2011 Date of latest renewal: 18 February 2016

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:

Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.